-
A New Milestone in Brain Tumor Imaging: FDA Approves Pixclara (floretyrosine F 18)
Advancing Glioma Diagnostics The landscape of neuro-oncology has seen a significant advancement with the recent FDA approval of Pixclara (floretyrosine F 18). This new radioactive diagnostic agent is set to change how clinicians visualize and manage gliomas, which are among the most challenging brain tumors to diagnose and monitor. Understanding Pixclara Pixclara is an amino…
-
A Significant Step Forward: First U.S. Patient Enrolled in BiPASS Phase 3 Study for Prostate Cancer Diagnosis
NASDAQ: $TLX Today marks an important milestone in the ongoing effort to improve the diagnosis and management of prostate cancer. We are excited to share news regarding the initiation of dosing for the first U.S. patient in the pivotal BiPASS Phase 3 clinical trial. This study focuses on assessing the performance of a novel diagnostic…